clinical trial · NCT06966479
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Severe AsthmaVerekitugPlacebo
brief summary
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
started
May 21, 2025
primary completion
Sep 1, 2027
completion
Sep 1, 2027
last updated
May 14, 2026
official title
A Long-Term Extension Study to Evaluate Safety and Efficacy of Verekitug (UPB-101) in Adult Participants With Severe Asthma Who Completed the VALIANT Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol